Early Initiation of Direct Oral Anticoagulants After Onset of Stroke and Short- and Long-Term Outcomes of Patients With Nonvalvular Atrial Fibrillation
Tadataka Mizoguchi, Kanta Tanaka, Kazunori Toyoda, Sohei Yoshimura, Ryo Itabashi, Masahito Takagi, Kenichi Todo, Masayuki Shiozawa, Yoshiki Yagita, Takeshi Yoshimoto, Tadashi Terasaki, Hiroshi Yamagami, Shunya Takizawa, Manabu Inoue, Kenji Kamiyama, Masafumi Ihara, Yasushi Okada, Takanari Kitazono, Masatoshi Koga, SAMURAI Study Investigators, Tadataka Mizoguchi, Kanta Tanaka, Kazunori Toyoda, Sohei Yoshimura, Ryo Itabashi, Masahito Takagi, Kenichi Todo, Masayuki Shiozawa, Yoshiki Yagita, Takeshi Yoshimoto, Tadashi Terasaki, Hiroshi Yamagami, Shunya Takizawa, Manabu Inoue, Kenji Kamiyama, Masafumi Ihara, Yasushi Okada, Takanari Kitazono, Masatoshi Koga, SAMURAI Study Investigators
Abstract
Background and Purpose- We aimed to compare outcomes of ischemic stroke patients with nonvalvular atrial fibrillation between earlier and later initiation of direct oral anticoagulants (DOACs) after stroke onset. Methods- From data for 1192 nonvalvular atrial fibrillation patients with acute ischemic stroke or transient ischemic attack in a prospective, multicenter, observational study, patients who started DOACs during acute hospitalization were included and divided into 2 groups according to a median day of DOAC initiation after onset. Outcomes included stroke or systemic embolism, major bleeding, and death at 3 months, as well as those at 2 years. Results- DOACs were initiated during acute hospitalization in 499 patients in median 4 (interquartile range, 2-7) days after onset. Thus, 223 patients (median age, 74 [interquartile range, 68-81] years; 78 women) were assigned to the early group (≤3 days) and 276 patients (median age, 75 [interquartile range, 69-82] years; 101 women) to the late (≥4 days) group. The early group had lower baseline National Institutes of Health Stroke Scale score and smaller infarcts than the late group. The rate at which DOAC administration persisted at 2 years was 85.2% overall, excluding patients who died or were lost to follow-up. Multivariable Cox shared frailty models showed comparable hazards between the groups at 2 years for stroke or systemic embolism (hazard ratio, 0.86 [95% CI, 0.47-1.57]), major bleeding (hazard ratio, 1.39 [95% CI, 0.42-4.60]), and death (hazard ratio, 0.61 [95% CI, 0.28-1.33]). Outcome risks at 3 months also did not significantly differ between the groups. Conclusions- Risks for events including stroke or systemic embolism, major bleeding, and death were comparable whether DOACs were started within 3 days or from 4 days or more after the onset of nonvalvular atrial fibrillation-associated ischemic stroke or transient ischemic attack. Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT01581502.
Keywords: anticoagulants; atrial fibrillation; humans; secondary prevention; stroke.
Source: PubMed